Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.
Brand Name : Ledaga
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 01, 2022
Lead Product(s) : Mechlorethamine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
